Plainsboro, N.J. (September 7, 2016) – The 34th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow (CFS) has announced that Atul Butte, MD, PhD, will deliver the keynote address at its annual meeting in November. Dr. Butte is recognized as a global expert in clinical informatics, a field that is guiding practitioners toward delivering more effective chemotherapy and other treatments for cancer and a range of other diseases.
 
CFS, sponsored by Physicians’ Education Resource^®, LLC (PER), annually brings together more than 2,000 oncologists, hematologists and other health care professionals from around the world to learn about state-of-the-art treatments across solid and hematologic malignancies and diverse clinical scenarios.
 
“We are pleased to welcome Dr. Butte as the keynote speaker at this year’s Chemotherapy Foundation Symposium. Dr. Butte’s cutting-edge work in the area of ‘big data’ analysis and clinical informatics continues to deliver valued information to the field and is forging a new path into establishing new strategies. Dr. Butte’s address is certain to be relevant and impactful for our attendees,” said Phil Talamo, president of PER.
 
Dr. Butte is the inaugural director of the Institute for Computational Health Sciences and a distinguished professor of pediatrics at the University of California, San Francisco. He also is the executive director for clinical informatics across the six University of California medical schools and medical centers and founder of three data-driven companies, including Personalis, which provides clinical interpretation of whole genome sequences. He has authored almost 200 publications, and his research into informatics has been featured in Wired Magazine, the New York Times and the Wall Street Journal.
 
The 34th Annual Chemotherapy Foundation Symposium will be held at the New York Marriott Marquis from Nov. 9 - 11. During the multi-day meeting, leading clinical investigators in almost every tumor subspecialty will provide insights on new developments in cancer therapeutics, including new compounds, novel approaches to diagnosis and treatment with current agents, ongoing clinical trials and emerging developments in cancer treatment and cure.
 
 
 
 
About PER^®
PER serves the oncology health care community, including physicians, fellows, advanced practice nurses, nurses, physician assistants, pharmacists and researchers. Since 1995, PER has been the educational resource of choice for live and online activities focusing on oncology and hematology, and provides high-quality, evidence-based activities featuring leading national and international faculty with a focus on practice-changing advances and standards of care in treatment and disease management. PER is part of the Plainsboro, N.J.-based Michael J. Hennessy Associates, Inc., family of businesses. Learn more at www.gotoper.com and www.mjhassoc.com.


Media Contact for PER:
Becky Taylor, 609-240-6886, [email protected]